Montelukast 6 Hónap És 5 Év Közötti Gyermekek Számára Teva (Montelukast Sodium)

Montelukast, the active ingredient in Montelukast 6 Hónap És 5 Év Közötti Gyermekek Számára Teva, is a leukotriene receptor antagonist presented as an oral formulation for use in children aged 6 months to 5 years. It treats asthma, exercise‑induced bronchoconstriction and allergic rhinitis in this pediatric population.

GNH USA supplies Montelukast 6 Hónap És 5 Év Közötti Gyermekek Számára Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast is a leukotriene receptor antagonist used in the management of respiratory and allergic conditions.

- Asthma: improves control of persistent asthma symptoms and reduces the frequency of exacerbations in children. - Exercise‑induced bronchoconstriction: prevents narrowing of the airways triggered by physical activity. - Allergic rhinitis: alleviates nasal congestion, sneezing and itching associated with seasonal allergies.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate pain in the head region. - Abdominal pain: discomfort or cramping in the stomach area. - Cough: occasional dry or productive cough. - Sore throat: irritation or pain in the throat. - Fever: transient elevation of body temperature. - Nausea: feeling of unease and urge to vomit.

Serious or Rare Side Effects: - Allergic reactions: rash, angioedema or anaphylaxis requiring immediate medical attention. - Neuropsychiatric events: mood changes, depression or suicidal thoughts. - Hepatic enzyme elevation: abnormal liver function tests. - Stevens‑Johnson syndrome: severe skin blistering and mucosal involvement. - Severe rash: widespread erythema or urticaria. - Eosinophilic granulomatosis with polyangiitis: rare vasculitic disorder.

When prescribing Montelukast, clinicians should consider several safety aspects.

- Dose adjustment: follow prescriber guidance based on the child's age and weight. - Monitor for neuropsychiatric symptoms: watch for mood changes, depression or suicidal ideation. - Avoid in patients with known hypersensitivity to montelukast or any component of the formulation. - Use cautiously in hepatic impairment: consider periodic liver function monitoring. - Pregnancy and lactation: safety not established; discuss risks with a healthcare professional. - Store at room temperature: keep in the original container, protect from moisture and heat.

Montelukast may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Phenobarbital: may lower montelukast plasma concentrations, reducing therapeutic effect. - Rifampin: can induce metabolism and decrease drug effectiveness. - Ketoconazole: may increase montelukast levels, raising risk of adverse reactions.

Moderate Interactions (Monitor Closely): - Beta‑agonists: additive bronchodilation may enhance respiratory effects. - Warfarin: occasional reports of altered INR; monitor coagulation parameters. - Epinephrine: potential for enhanced cardiovascular responses; observe patient closely.